Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Long-Term Investments (2017 - 2025)

Historic Long-Term Investments for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $11.8 million.

  • Innate Pharma's Long-Term Investments rose 552.02% to $11.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $11.8 million, marking a year-over-year increase of 552.02%. This contributed to the annual value of $11.0 million for FY2024, which is 423.46% up from last year.
  • Per Innate Pharma's latest filing, its Long-Term Investments stood at $11.8 million for Q2 2025, which was up 552.02% from $11.0 million recorded in Q4 2024.
  • Innate Pharma's Long-Term Investments' 5-year high stood at $48.3 million during Q2 2021, with a 5-year trough of $10.5 million in Q4 2023.
  • Moreover, its 5-year median value for Long-Term Investments was $35.8 million (2022), whereas its average is $27.8 million.
  • Its Long-Term Investments has fluctuated over the past 5 years, first tumbled by 9986.91% in 2021, then soared by 552.02% in 2025.
  • Over the past 5 years, Innate Pharma's Long-Term Investments (Quarter) stood at $45.6 million in 2021, then decreased by 21.46% to $35.8 million in 2022, then plummeted by 70.58% to $10.5 million in 2023, then rose by 4.23% to $11.0 million in 2024, then rose by 7.05% to $11.8 million in 2025.
  • Its Long-Term Investments stands at $11.8 million for Q2 2025, versus $11.0 million for Q4 2024 and $11.1 million for Q2 2024.